Clinical Trial Update: Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing two daily doses of SPD476 (mesalazine) with reference therapy in acute mild-to-moderate ulcerative colitis to assess efficacy and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Asacol (mesalamine)
• SPD476

Snippet

Sponsor: Shire | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED